Quick Answer Adicet Bio, Inc. reported R&D Expense of $99.13 million for fiscal year 2025. Adicet Bio, Inc. R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $99.13M -0.2% 2024 $99.32M -6.3% 2023 $106.04M +48.8% 2022 $71.25M +45.6% 2021 $48.94M +42.5% 2020 $34.33M +44.9% 2019 $23.69M +61.0% 2018 $14.72M -12.6% 2017 $16.84M … Read more
Quick Answer Adicet Bio, Inc. reported Stockholders Equity of $159.21 million for fiscal year 2025. Adicet Bio, Inc. Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $159.21M -14.7% 2024 $186.61M +9.7% 2023 $170.18M -41.8% 2022 $292.34M -3.6% 2021 $303.13M +176.0% 2020 $109.83M +281.9% 2019 -$60.37M -80.1% 2018 -$33.52M -24.4% 2017 -$26.95M … Read more
Quick Answer Adicet Bio, Inc. reported Cash and Equivalents of $38.92 million for fiscal year 2025. Adicet Bio, Inc. Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $38.92M -31.1% 2024 $56.49M -64.6% 2023 $159.71M -38.0% 2022 $257.66M -7.2% 2021 $277.54M +229.1% 2020 $84.33M +695.0% 2019 $10.61M +11.9% 2018 $9.47M … Read more
Quick Answer Adicet Bio, Inc. reported Total Assets of $192.35 million for fiscal year 2025. Adicet Bio, Inc. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $192.35M -12.7% 2024 $220.22M +6.2% 2023 $207.29M -37.3% 2022 $330.69M -2.4% 2021 $338.94M +120.3% 2020 $153.84M +88.6% 2019 $81.59M -25.8% 2018 $109.94M +99.2% 2017 $55.19M … Read more
Quick Answer Adicet Bio, Inc. reported Diluted EPS of $16.95 per share (loss) for fiscal year 2025. Adicet Bio, Inc. Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 -$16.95 +20.5% 2024 -$21.33 -544.4% 2023 -$3.31 -94.7% 2022 -$1.70 +15.0% 2021 -$2.00 — Quarterly Diluted EPS Quarter Ending Diluted EPS YoY QoQ … Read more
Quick Answer Adicet Bio, Inc. reported Net Income of -$116.80 million for fiscal year 2025. Adicet Bio, Inc. Net Income — Annual History Fiscal Year Net Income YoY Change 2025 -$116.80M +0.3% 2024 -$117.12M +17.9% 2023 -$142.66M -104.4% 2022 -$69.79M -12.6% 2021 -$62.00M -69.0% 2020 -$36.68M -30.4% 2019 -$28.14M -202.6% 2018 -$9.30M +72.5% 2017 -$33.78M … Read more
Quick Answer Adicet Bio, Inc. reported Net Income of -$116.80 million for fiscal year 2025. Adicet Bio, Inc. — Key Financials by Year Metric 2025 2024 2023 2022 2021 2020 Net Income -$116.80M+0.3% -$117.12M+17.9% -$142.66M-104.4% -$69.79M-12.6% -$62.00M-69.0% -$36.68M-30.4% Diluted EPS -$16.95+20.5% -$21.33-544.4% -$3.31-94.7% -$1.70+15.0% -$2.00 — Total Assets $192.35M-12.7% $220.22M+6.2% $207.29M-37.3% $330.69M-2.4% $338.94M+120.3% $153.84M+88.6% Cash … Read more
Quick Answer Accel Entertainment, Inc. reported Operating Income of $107.85 million for fiscal year 2025. Accel Entertainment, Inc. Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 $107.85M +18.7% 2024 $90.88M -15.4% 2023 $107.41M +10.9% 2022 $96.86M +38.0% 2021 $70.19M +384.4% 2020 -$24.68M -285.1% 2019 $13.34M -46.4% 2018 $24.87M +36.9% 2017 $18.17M … Read more
Quick Answer Accel Entertainment, Inc. reported Shares Outstanding of 93.41 million shares for fiscal year 2021. Accel Entertainment, Inc. Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2021 93.41M +0.0% 2020 93.38M +21.8% 2019 76.64M — Quarterly Shares Outstanding Quarter Ending Shares Outstanding YoY QoQ March 31, 2023 86.44M — -0.3% December … Read more
Quick Answer Accel Entertainment, Inc. reported Stockholders Equity of $269.68 million for fiscal year 2025. Accel Entertainment, Inc. Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $269.68M +5.7% 2024 $255.03M +28.5% 2023 $198.40M +11.1% 2022 $178.59M +12.7% 2021 $158.46M +23.9% 2020 $127.87M +4.6% 2020 $122.28M +271.2% 2020 $32.95M -44.8% 2020 $59.71M … Read more